Sarepta Therapeutics, Inc. 8-K

What Happened

• Sarepta Therapeutics, Inc. announced its quarterly financial results for the quarter ended March 31, 2026 via a press release dated May 6, 2026. The company furnished the press release as Exhibit 99.1 to its Current Report on Form 8-K (Item 2.02 reporting results of operations and financial condition).

Key Details

• Filing date: May 6, 2026 (Form 8-K).
• Period reported: Quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the 8-K.
• Report signed by Douglas S. Ingram, Chief Executive Officer.

Why It Matters

• Quarterly earnings releases provide the headline metrics investors use to assess revenue, earnings, cash flow and operational trends. This 8-K notifies the market that Sarepta has published its Q1 2026 results; investors should review the Exhibit 99.1 press release for the full financial figures and await the company’s periodic filings (such as the Form 10-Q) for detailed financial statements and management discussion.